Introduction
============

Congenital heart defects (CHDs) are the most common birth defects in humans, with a prevalence of 0.8% ([@B21]; [@B57]). The etiology of most CHDs is unknown but is thought to involve multiple genetic, epigenetic, environmental, and lifestyle factors ([@B7]; [@B43]; [@B21]; [@B57]; [@B49]). Only about 15 to 20% of CHDs can be attributed to known causes, with 5 to 10% of cases with CHDs showing chromosomal abnormalities ([@B6]; [@B21]). Trisomy 21 (OMIM 190685), which results in Down syndrome (DS), shows the highest association with major heart abnormalities, which are present in approximately 40 to 60% of individuals with DS. Such CHDs typically involve septal defects such as atrial septal defects, ventricular septal defects, and complete atrioventricular canal defects ([@B27]; [@B39]). In addition to the direct effects of the chromosomal abnormality, maternal genotype, diet, and lifestyle factors, along with environmental exposures, may be involved in the development of heart anomalies in individuals with DS. Foremost among these maternal risk factors are folic acid deficiency and genetic variations of folate pathway genes, such as the methylenetetrahydrofolate reductase gene (*MTHFR*) ([@B10]; [@B33]; [@B16]; [@B1]). Altered maternal DNA methylation is suggested to be an underlying mechanism in the development of birth defects, including CHDs ([@B5]; [@B14]; [@B2]; [@B46]; [@B47]). Some risk factors have been proposed to modulate DNA methylation, including aging, body mass index (BMI), cigarette smoking, alcohol intake, folate deficiency, *MTHFR* polymorphisms, and hyperhomocysteinemia patterns ([@B14]; [@B26]; [@B50]; [@B64]; [@B19]; [@B40]; [@B41]; [@B59]; [@B38]).

During the last decade, quantitative measurement of the methylation status of long interspersed nucleotide element-1 (LINE-1) in white blood cells (WBCs) has been used as a surrogate measure of global DNA methylation and as a potential biomarker in a variety of diseases ([@B61]; [@B14]). Maternal LINE-1 hypomethylation has been linked to an increased risk of non-syndromic CHD, particularly septal defects ([@B14]). We previously found significantly lower levels of LINE-1 methylation in the mothers of children with DS than in the mothers of healthy children ([@B8]). However, the relationship between LINE-1 methylation and DS-associated CHD has not yet been investigated.

Thus, the aim of the present study was to assess (i) the association between maternal LINE-1 methylation and the occurrence of CHD in children with DS and (ii) the association of endogenous maternal factors (*MTHFR* C677T polymorphism and maternal age), and exogenous maternal factors (cigarette smoking, alcohol intake, medication use, body mass index, and dietary habits, such as folate intake) with LINE-1 methylation in mothers of children with DS and CHD.

Materials and Methods {#s1}
=====================

Study Participants
------------------

The study population consisted of 90 mothers of children with maternally derived full trisomy 21. All participants were the same ethnicity (Caucasian); 49% (44/90) had children with DS and CHD (DS-CHD^+^ mothers), and 51% (46/90) had children with DS without CHD (DS-CHD^−^ mothers). There was a septal defect in 82% (36/44) of the children with DS-CHD^+^, a patent foramen ovale in 11% (5/44), patent ductus arteriosus in 5% (2/44), and persistent truncus arteriosus in 2% (1/44). Information about CHD was obtained from each child's medical records. Maternal blood samples were collected in collaboration with DS associations in larger cities in Croatia (Rijeka, Zagreb, Pula, Zadar, Split, Karlovac, Čakovec, and Osijek). The Ethics Committee of the School of Medicine, University of Rijeka, reviewed and approved all study protocols (reference number: 2170-24-01-13-04). Written informed consent was provided by all participants prior to participation in the study in accordance with the Declaration of Helsinki. Before the sampling, the mothers were asked to complete a specially created questionnaire that asked about demographic data, weight and height, intake of folate-rich foods, cigarette smoking, alcohol intake, and medication use. The questionnaire was adapted from a food frequency questionnaire that has been validated for Croatian women ([@B15]).

Genetic Analysis
----------------

Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp DNA Blood FlexiGene DNA Kit (Qiagen, Hilden, Germany). Quantification of genomic DNA was performed using a spectrophotometer (BioMateTM3, Thermo Electron Corporation, United States). The parental origin of trisomy 21 was determined as described previously ([@B58]). The *MTHFR* C677T polymorphism was evaluated using polymerase chain reaction--restriction fragment length polymorphism (PCR-RFLP) ([@B17]). Using the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany), 500 ng of genomic DNA was subjected to sodium bisulfite modification and resuspended in 30 μl of TE buffer. Bisulfite-treated DNA was diluted 10×, and 8.18 μl was used for each real-time PCR reaction. All samples were stored at −20°C until analysis.

LINE-1 DNA methylation was analyzed by quantifying LINE-1 methylation using previously developed and validated MethyLight methodology, which precision and reproducibility have been well described ([@B22]; [@B61]; [@B14]; [@B8]). The PCR primers and probes for LINE-1 and for Alu sequences (ALU-C4) (Applied Biosystems, Forest City, CA, United States) were designed/validated ([@B61]) and described previously ([@B61]; [@B8]). The LINE-1 primers lack CpG sites and the specific TaqMan MGB probes (corresponding to the methylated and unmethylated LINE-1 sequence after bisulphite treatment) were used in real-time PCR (Applied Biosystems, Forest City, CA, United States). An Alu-based real-time PCR control reaction was performed in parallel with each LINE-1 real-time PCR reaction to normalize DNA input, as previously described ([@B61]; [@B8]). PCR reactions were performed with a final reaction volume of 25 μl in sealed 96-well plates on the ABI 7500 Real-Time PCR System (Applied Biosystems). The PCR reactions and cycle conditions for the LINE-1 and ALU-C4 assays were described previously ([@B8]). Real-time PCR was performed in duplicate for each sample. The standard curve was established using EpiTect Methylated Control DNA and EpiTect Unmethylated Control DNA (Qiagen), as described previously ([@B8]). After PCR amplification, the data were read using SDS 1.4.0 software (Applied Biosystems). The percentage of methylated reference (PMR) and the percentage of unmethylated reference (PUR) were calculated, and the final percentage of LINE-1 DNA methylation was calculated according to the formula PMR/(PMR+PUR) × 100 ([@B22]; [@B61]; [@B8]). After all runs we randomly repeated runs for 10% of all samples and we have complete reproducibility of the results.

The Influence of Endogenous and Exogenous Factors on Maternal LINE1 DNA Methylation
-----------------------------------------------------------------------------------

The analysis included maternal age and BMI as continuous variables and folate supplement intake, cigarette smoking, alcohol intake, and medication use as categorical variables. BMI was also studied as a categorical variable ("WHO BMI"), and four groups were defined according to WHO classification: underweight, normal, overweight, and obese. Because the impact of folic acid intake is modified by genes that code for enzymes involved in folate metabolism, the analysis also included the variable "*MTHFR* C677T genotype/diet," which was used to indicate the combination of the *MTHFR* C677T polymorphism and dietary folate intake (rich or poor) ([@B28]; [@B13]). A folate-rich diet was defined as the consumption of at least three folate-rich foods (green leafy vegetables, legumes, veal liver, fruit, corn flakes, muesli) at least 2--3 times each week; lower intake was considered a low-folate diet. Mothers who consumed folic acid daily from 4 weeks before conception until 8 weeks after conception were considered to be periconceptional folic acid users. The questionnaire asked about cigarette smoking, alcohol intake, and medication use both (i) during the first 6 weeks of pregnancy and (ii) currently. Mothers who consumed one glass of wine or one glass of beer or one small strong alcoholic drink at least one time per week were defined as alcohol consumers. Those who smoked cigarettes daily or occasionally were classified as smokers.

Statistical Analysis
--------------------

Differences in the frequencies between the investigated groups of participants were estimated by the chi-square test. Continuous variables with skewed distribution between groups were compared using the Mann--Whitney *U*-test. Normally distributed continuous variables were compared using analysis of variance (ANOVA) with the Bonferroni *post hoc* test and are reported as means and standard deviations (SDs). Logistic regression was used to determine the odds ratio and 95% confidence interval for the association between *MTHFR* C677T polymorphism and the occurrence of CHD in children with DS. Multivariate regression analysis was used to estimate the effects of the endogenous and exogenous factors included in the model on LINE1 DNA methylation (*MTHFR* C677T polymorphism, age, BMI, dietary intake of folate, intake of folate supplements, smoking, alcohol intake, and medication use), and the results are presented as regression coefficient (beta) values plus the standard error (SE). Statistical significance was considered for *P \<* 0.05. Data analysis was performed using Statistica for Windows 10.0 (StatSoft, Tulsa, OK, United States).

Results
=======

[Table 1](#T1){ref-type="table"} shows the characteristics of the study participants. DS-CHD^+^ mothers were significantly younger than DS-CHD^−^ mothers (*P* = 0.003). The frequency of mothers who smoked cigarettes during the first 6 weeks of pregnancy was significantly higher in DS-CHD^+^ mothers than in DS-CHD^−^ mothers (*P* = 0.005).

###### 

Characteristics of mothers of children with Down syndrome (DS) with or without congenital heart defects (CHDs).

                                                                   DS-CHD^+^ mothers      DS-CHD^−^ mothers      *P*-value
  ---------------------------------------------------------------- ---------------------- ---------------------- -----------
  Median age, years (min--max)                                     37 (24--59)            42 (28--64)            0.00
  Median BMI (min--max)                                            24.19 (17.19--35.43)   26.01 (17.71--40.40)   0.09
  **Diet N (%)**                                                                                                 
  Folate-rich                                                      16 (36)                21 (46)                0.24
  Low-folate                                                       28 (64)                45 (54)                
  **Intake of folic acid supplements N (%)**                                                                     
  No                                                               25 (57)                33 (72)                0.14
  Yes                                                              19 (43)                13 (28)                
  **Periconceptional folic acid intake**                                                                         
  No                                                               41 (93)                46 (100)               0.17
  Yes                                                              3 (7)                  0 (0)                  
  **Smoking during the first 6 weeks of pregnancy N (%)**                                                        
  No                                                               15 (34)                29 (63)                0.00
  Yes                                                              29 (66)                17 (37)                
  **Currently smoking N (%)**                                                                                    
  No                                                               27 (71)                33 (72)                0.21
  Yes                                                              17 (39)                13 (28)                
  **Alcohol intake during the first 6 weeks of pregnancy N (%)**                                                 
  No                                                               31 (70)                33 (72)                0.54
  Yes                                                              13 (30)                13 (28)                
  **Current alcohol intake N (%)**                                                                               
  No                                                               32 (73)                37 (80)                0.27
  Yes                                                              12 (30)                9 (20)                 
  **Medication use during the first 6 weeks of pregnancy N (%)**                                                 
  No                                                               38 (86)                39 (85)                0.53
  Yes                                                              6 (14)                 7 (15)                 
  **Current medication use N (%)**                                                                               
  No                                                               42 (95)                43 (93)                0.52
  Yes                                                              2 (5)                  3 (7)                  

P-values were determined using the Mann--Whitney test or the chi-square test.

[Supplementary Table S1](#SM1){ref-type="supplementary-material"} shows the allele and genotype frequencies of the *MTHFR* C677T polymorphism in DS-CHD^+^ and DS-CHD^−^ mothers. There were no significant differences between the two groups.

Maternal LINE1 DNA Methylation
------------------------------

There was no significant difference in LINE-1 methylation between DS-CHD^+^ mothers (median: 95.30%; min--max: 88.68--99.90%) and DS-CHD^−^ mothers (median: 95.51%; min--max: 79.13--99.73%) (*P* = 0.997). The difference in LINE-1 methylation between these groups remained non-significant after adjusting for two factors that were significantly different between these groups, namely maternal age and smoking during the first 6 weeks of pregnancy (adjusted OR = 1.03, 95% CI: 0.876--1.173, *P* = 0.853).

We have shown in [Table 2](#T2){ref-type="table"} the values of LINE-1 methylation in DS-CHD^+^ mothers according to WHO BMI categories. Those in the highest WHO BMI category (≥30 kg/m2) had significantly lower LINE-1 methylation than those in either the normal WHO BMI category (Bonferroni *post hoc P* = 0.03) or the overweight WHO BMI category (Bonferroni *post hoc P* = 0.04). [Table 3](#T3){ref-type="table"} lists the values for LINE-1 methylation in DS-CHD^+^ mothers according to *MTHFR* C677T genotype/diet combinations. The lowest LINE-1 DNA methylation values were observed in mothers with the CT+TT genotype and a low-folate diet. We performed multivariate regression analysis in order to evaluate the independent effect of the investigated parameters on LINE-1 DNA methylation in DS-CHD^+^ mothers. Among the investigated predictors ([Table 4](#T4){ref-type="table"}), only the *MTHFR* C677T genotype/diet combination and BMI were significantly independently associated with LINE-1 DNA methylation in DS-CHD^+^ mothers (β -0.40, *P* = 0.01 and β-0.32, *P* = 0.03, respectively).

###### 

LINE-1 methylation in mothers of children with DS with congenital heart defects (CHDs) according to World Health Organization (WHO) body mass index (BMI) category.

  WHO-BMI      DNA LINE1 methylation (%) Means   DNA LINE1 methylation, SE   *N*
  ------------ --------------------------------- --------------------------- -----
  18.5         93.77                             1.87                        2
  18.5--24.9   95.86                             0.55                        23
  25--29.9     96.08                             0.76                        12
  ≥30          92.50^∗^                          1.00                        7

ANOVA P = 0.02;

∗

Bonferroni post hoc, BMI ≥ 30 vs. BMI 25--29.9, P = 0.04; BMI ≥ 30 vs. BMI 18.5--24.9, P = 0.03, N = 44.

###### 

LINE-1 methylation in mothers of children with DS with congenital heart defects (CHDs) according to the *MTHFR* C677T genotype/diet combination.

  *MTHFR* C677T genotype/diet   DNA LINE1 methylation (%) Means   DNA LINE1 methylation SE   *N*
  ----------------------------- --------------------------------- -------------------------- -----
  CC/folate-rich diet           97.69                             0.89                       9
  CT+TT/folate-rich diet        94.94                             1.01                       7
  CC/folate-poor diet           94.68                             0.77                       12
  CT+TT/folate-poor diet        94.55^∗^                          0.67                       16

ANOVA P = 0.04,

∗

Bonferroni post hoc CT+TT/folate-poor diet, N = 44.

###### 

Multivariate analysis of predictors that influence LINE-1 methylation in mothers of children with DS with congenital heart defects (CHDs).

  Predictors included in the analysis   Beta    Standard error of beta   *P*-level
  ------------------------------------- ------- ------------------------ -----------
  Currently smoking                     0.10    0.16                     0.53
  Current alcohol intake                0.08    0.15                     0.57
  Current medication use                −0.20   0.14                     0.17
  BMI                                   −0.32   0.14                     0.03
  Periconceptional folic acid intake    −0.01   0.15                     0.96
  *MTHFR* C677T genotype/diet           −0.40   0.15                     0.01
  Age of mother                         −0.22   0.15                     0.14

R = 0.58, R

2

= 0.34, adjusted R

2

= 0.21, P \< 0.028.

In addition, we determined the LINE-1 methylation values in mothers of children with DS and septal defects. We found that the *MTHFR* C677T genotype/diet combination significantly influenced LINE-1 DNA methylation ([Table 5](#T5){ref-type="table"}). There were no statistically significant associations with LINE-1 methylation identified in DS-CHD^−^ mothers ([Supplementary Tables S2](#SM1){ref-type="supplementary-material"}--[S4](#SM1){ref-type="supplementary-material"}).

###### 

Multivariate analysis of predictors that influence LINE-1 methylation in mothers of children with DS with septal defects.

  Predictors included in the analysis   Beta    Standard error of beta   *P*-value
  ------------------------------------- ------- ------------------------ -----------
  Intercept                                                              0.00
  BMI                                   −0.27   0.15                     0.08
  *MTHFR* C677T genotype/diet           −0.36   0.15                     0.02

R = 0.47, R

2

= 0.23, adjusted R

2

= 0.18, P \< 0.015.

Discussion
==========

To the best of our knowledge, this is the first study to investigate the impact of endogenous maternal factors (*MTHFR* C677T polymorphism and maternal age) and exogenous maternal factors (cigarette smoking, alcohol intake, medication use, body mass index, dietary habits such as folate intake) on LINE-1 methylation in the mothers of children with DS regarding the presence of DS-associated CHDs, particularly regarding the presence of septal defect. The molecular mechanisms that underlie the epigenetic regulation of gene transcription are independent of DNA sequence, but they do depend on environmental stimuli, such as periconceptional maternal supplementation, diet, and the in utero environment ([@B2]; [@B52]). The morphological processes that accompany embryonic heart development remain largely unknown, but multiple genetic, epigenetic, environmental, and lifestyle factors likely influence this process ([@B43]; [@B57]; [@B25]; [@B31]; [@B52]).

We found that BMI and the *MTHFR* genotype/diet combination were significantly associated with variations in LINE-1 DNA methylation in DS-CHD^+^ mothers. Lower LINE1 DNA methylation values were significantly associated with the genotype containing the *MTHFR* 677T allele in combination with a low folate diet as well as with higher BMI, which is in accordance with previous studies ([@B28]; [@B13]; [@B44]; [@B11]). Notably, it was reported previously that higher BMI is associated with lower LINE-1 methylation values in women of childbearing age ([@B44]). The association between a maternal BMI that is higher than recommended by WHO and the occurrence of CHD in their offspring is well documented ([@B48]; [@B44]; [@B4]; [@B11]). It is in line with our finding of significant influence of BMI only in the DS-CHD^+^ mothers. The mechanism by which BMI influences the development of CHD is not well understood, but it is thought that obesity is linked to lower concentrations of folate in the blood as well as with undiagnosed diabetes, both of which are maternal risk factors for CHD development ([@B35]; [@B3]; [@B53]; [@B12]; [@B48]; [@B33]). Likewise, increasing evidence suggests that folate metabolism and the resulting epigenetic modifications may contribute to the occurrence of CHD in individuals with DS ([@B10]; [@B23]; [@B16]).

DNA synthesis and methylation, processes that are folate-dependent, increase during pregnancy ([@B42]). Folate pathway genes have been extensively investigated in regard to their association with CHD ([@B56], [@B54]; [@B60]; [@B23]). The MTHFR enzyme plays a key role in the regulation of folate availability in DNA synthesis and methylation. The C677T is one of the most important functional polymorphisms of the MTHFR gene ([@B29]). Numerous studies have investigated the association between the *MTHFR* C677T polymorphism and the risk of CHDs, but the results have been inconsistent ([@B34]; [@B66]; [@B10]; [@B9]). Meta-analyses showed that maternal *MTHFR* C677T polymorphism may contribute to the risk of CHDs ([@B60]; [@B62]; [@B63]). Research on the relationship between the maternal *MTHFR* genotype and the development of CHD in children with DS has also yielded conflicting results ([@B10]; [@B33]; [@B9]; [@B23]; [@B16]). There has not yet been a meta-analysis, but almost all studies have shown that the *MTHFR* C677T genotype may be a maternal risk factor for CHD in children with DS, particularly if the mothers did not consume folic acid during the periconceptional period ([@B10]; [@B23]).

It is well established that increased folate intake can neutralize the impact of the *MTHFR* C677T polymorphism and restore normal enzyme activity ([@B32]; [@B37]). Thus, a number of studies suggest that periconceptional maternal folic acid use has a protective effect on the occurrence of CHD in offspring, particularly for septal defects ([@B18]; [@B7]; [@B55]). In our study, the periconceptional use of folate was not significantly associated with the level of LINE-1 methylation by itself. However, dietary folate intake in combination with the *MTHFR* C677T genotype showed a significant association with LINE-1 methylation levels. Moreover, our results revealed that the values of LINE-1 DNA methylation in DS-CHD^+^ mothers, as well as in the mothers of children with DS and septal defects, were clearly stratified according to the *MTHFR* C677T genotype/diet combination: the lowest values were observed in mothers with the CT+TT genotype and a low-folate diet, and the highest levels were observed in mothers with the CC genotype and a folate-rich diet. Chowdhury et al. also reported significant LINE-1 hypomethylation in women with children affected by septal defects ([@B14]).

We found that the *MTHFR* C677T genotype/low folate diet combination was significantly associated with LINE-1 hypomethylation in mothers with children with DS who developed septal defects, and our previous study showed that significant LINE-1 hypomethylation (compared to controls) in the mothers of children with DS was itself significantly associated with the *MTHFR* C677T genotype/diet combination ([@B8]). Since the maternal environment potentially affects the fetus during pregnancy ([@B20]), it is important that the analysis include as many factors as possible that could influence fetal development. In the present study, the *MTHFR* C677T genotype/diet combination and BMI showed a univariate association with LINE-1 DNA methylation in DS-CHD^+^ mothers. In addition, these parameters were independently associated with of LINE-1 DNA methylation in a multivariate analysis that included other maternal risk factors, such as smoking, periconceptional folic acid intake, medication and alcohol use, and age. In the multivariate model (model *P \<* 0.028), these two factors explained around 72% of the variance in LINE-1 DNA methylation in DS-CHD^+^ mothers. Factors like cigarette smoking, alcohol intake, and age showed no associations with LINE-1 methylation status, which is in accordance with other studies ([@B50]; [@B65]; [@B36]). Medication use was not significantly associated with LINE-1 DNA methylation, although only 6% of the participants were taking medications, and these belonged to several different therapeutic groups. Thus, we do not currently have enough data to discuss whether certain medications influence LINE-1 DNA methylation.

This study has several limitations. Notably, approximately 1/3 of fetuses with trisomy 21 are lost during early pregnancy ([@B45]). Thus, the true prenatal incidence of CHD in fetuses with trisomy 21 is unknown, and we can only speculate that those lost during early pregnancy may be more affected by CHDs than those who are born alive. Several studies have indicated that the increase of the prevalence of cardiac anomalies with decreasing fetal gestational age contributes to higher numbers of miscarriages ([@B30]; [@B51]). Tomek et al. reported that the spectrum of CHDs that are diagnosed prenatally differs significantly from the spectrum of CHDs diagnosed postnatally in that there is a markedly higher proportion of additional abnormalities associated with those who are diagnosed prenatally ([@B51]). Thus, we would have a clearer picture of the impact of maternal LINE-1 DNA methylation on DS-associated CHDs if we could analyze the maternal LINE-1 DNA methylation values during pregnancy (and thus during organogenesis) for all conceived fetuses with trisomy 21, since during this time, altered maternal DNA methylation would exert the greatest effects. It is possible that increases in cellular proliferation and carbon metabolism during pregnancy, as well as an increased demand for methyl groups during embryonic development, could have an even greater influence on maternal LINE-1 DNA methylation and contribute to the development of CHD in offspring. Given the rare prevalence of DS-associated CHD, the resources and sample size required to conduct such a study, and the difficulty in enrolling women before conception and monitoring them until the completion of their pregnancy, it would be very challenging to conduct this type of study. Also, analysis of other class of repetitive elements, such as ALU, might give additional information on the global DNA methylation in mothers of children with DS with regard to presence of CHD. It was suggested that Alu might be more informative in background where the LINE-1 hypomethylation might be influenced by genomic instability, carcinogenesis or aging ([@B24]).

In conclusion, we have not found the association of maternal LINE-1 methylation with CHD in children with DS. Yet, we have found significant association of the *MTHFR* genotype/diet combination and BMI with LINE-1 methylation in mothers of children with DS-CHD and in mothers of children with DS and septal defects. These results strongly support the need for a multifactorial approach in analysis of endogenous and exogenous maternal factors that could affect or are associated with maternal LINE-1 DNA methylation and the consequent pathologies in children. More extensive studies in a larger sample may help to validate these results while functional studies are inevitable to elucidate the causality and mechanisms of action of proposed factors.
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